Articles for author: The whipping post

The whipping post

Most Popular

Insightful Investments: AI Stocks to Watch in 2024 Insightful Investments: AI Stocks to Watch in 2024

As the stock market takes a breather after a year of extraordinary gains, investors are understandably cautious. The Nasdaq Composite (NASDAQINDEX: ^IXIC) notched an impressive 43% increase last year, leaving many to question the sustainability of the current rally. Yet looking back to 1972, in the years following a bear market rebound, the Nasdaq has ...

The whipping post

Most Popular

Netflix Surges: Could it Outpace Meta Platforms by 2025?

Netflix Flies in the Face of Bears Netflix’s recent financial ascent has left naysayers gobsmacked. The company’s stock skyrocketed by 11% on Jan. 24 following the revelation of its fourth-quarter earnings, which unveiled a remarkable 12.5% year-over-year revenue surge to $8.83 billion. Simultaneously, its net income experienced a staggering 1,605% leap to $938 million, or ...

The whipping post

Most Popular

Profitable Opportunity in New Ford Motor Options

Exploring New Options New options have become available for Ford Motor Co. (Symbol: F) with the July 19th expiration, presenting a potential opportunity for sellers of puts or calls to achieve a higher premium due to the time value with 175 days until expiration. This allows for a potential alternative to the current stock price ...

The whipping post

Most Popular

Top Retail Stocks En Route to Triumph Top Retail Stocks to Accelerate Your Portfolio Growth

An Awe-Inspiring Retail Boom The retail sector, encompassing traditional brick-and-mortar stores and e-commerce behemoths, is poised for a resurgence. Fueled by anticipated increases in consumer expenditure amid abating inflationary constraints and the potential for impending interest rate cuts, the retail realm is flashing a beacon of promise. To unearth the creme de la creme of ...

The whipping post

Most Popular

The Good, the Bad, and the Ugly: Cramer’s Take on BlackRock, SolarEdge, and Axsome Therapeutics

BlackRock, Inc.’s Stellar Performance Reflecting on the recent market actions, Jim Cramer couldn’t help but commend BlackRock, Inc.’s sensational quarterly performance. He urged investors to consider investing in the company, emphasizing the magnitude of the achievement. Due to the postponement of the SEC’s decision on BlackRock’s proposed Ethereum exchange-traded fund, investors will have to wait ...

The whipping post

Most Popular

Is It Time to Invest in Intel’s Stock? Should Investors Buy the Dip in Intel’s Stock After Earnings?

Intel is feeling the pain in the stock market, with a dramatic 12% tumble in today’s trading session following the release of their favorable Q4 results after market hours on Thursday. However, the chip giant provided underwhelming guidance for the first quarter, which sent investor sentiment plunging. But despite the recent dip, it’s important to ...

The whipping post

Most Popular

Record Highs & Tumbles: This Week in the Financial Markets Record Highs & Tumbles: This Week in the Financial Markets

In a week fraught with wild stock market fluctuations, the three major U.S. stock market indices collectively soared to unprecedented peaks. The fuel for this stratospheric rise was primarily stoked by investor optimism surrounding AI-driven ventures and the proactive anticipation of forthcoming Federal Reserve rate cuts. The undeniably robust U.S. economy, buoyed by robust consumer ...

The whipping post

Most Popular

3 Stand-Out Stocks to Consider After Earnings Reports 3 Stand-Out Stocks to Consider After Earnings Reports

Impressive Quarterly Performances Quarterly results from notable companies such as Netflix and Tesla have drawn substantial attention this week. However, amid this busy earnings lineup, several lesser-known names have managed to catch the eye with their impressive earnings reports. PACCAR: Setting New Benchmarks PACCAR, an auto company, emerged as a prominent performer this week. The ...

The whipping post

Most Popular

Corbus Pharma’s Remarkable Surge Corbus Pharmaceuticals’ Remarkable Surge After Early Phase 1 Data on Tumor Candidate

Shares of micro-cap biotech company Corbus Pharmaceuticals (NASDAQ:CRBP) skyrocketed over 300% on Friday following the announcement of early, yet promising, data from a small group of cancer patients who were treated with its antibody-drug conjugate CRB-701 in a Phase 1 trial. Based on the data cut in December for patients with cancers expressing the tumor-associated ...